Zhenxing Biopharmaceutical & Chemical Inc operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Zhenxing Biopharmaceutical & Chemical Inc with three other
companies in this sector in China:
Walvax Biotechnology Company Limited
sales of 590.16 million Chinese Renmimbi [US$85.70 million]
of which 38%
was Autonomous Vaccine),
Pulike Biological Engineering Inc
(583.09 million Chinese Renmimbi [US$84.68 million]
of which 93%
was Veterinary Chemicals), and
Shenzhen Kangtai Biological Products Co Ltd
(551.87 million Chinese Renmimbi [US$80.14 million]
of which 99%
was Biological products).
During the year ended December of 2016, sales at
Zhenxing Biopharmaceutical & Chemical Inc were 567.44 million Chinese Renmimbi (US$82.40 million).
increase of 13.4%
versus 2015, when the company's sales were 500.27 million Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Zhenxing Biopharmaceutical & Chemical Inc
(and since 2011, sales have increased a total of 23%).
Sales of Pharmaceutical Sales saw an increase
14.3% in 2016, from
495.41 million Chinese Renmimbi to 566.06 million Chinese Renmimbi.
Not all segments of Zhenxing Biopharmaceutical & Chemical Inc experienced an increase in sales in 2016:
sales of Other Industry fell 71.8% to 1.37 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).